Our study, which represents the largest cohort to date using the 22C3 assay, provides a more robust estimate of the prevalence of high baseline PD-L1 expression in EGFR-mutated lung adenocarcinoma within real-world clinical practice. Here, EGFR is linked to lung adenocarcinoma.